CVS Group plc Block Listing Interim Review (4644Z)

TIDMCVSG

RNS Number : 4644Z

CVS Group plc

12 January 2024

CVS Group plc

("CVS" or the "Company")

Block Listing Interim Review

CVS, one of the UK's leading providers of integrated veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").

 
 Name of the company:            CVS Group plc 
 Name of relevant scheme:             1. CVS Group plc 2017-2020 Sharesave Scheme; 
                                       2. CVS Group plc 2018-2021 SAYE Sharesave 
                                       Scheme; and 
                                       3. CVS Group SAYE Plan 
                                       4. CVS Long Term Incentive Plan 2017 
                                ------------------------------------------------------ 
 Period           From:          1 2 July 2023            To:    12 January 2024 
  of return: 
                 -------------  -----------------------  -----  ---------------------- 
 Balance of unallotted                1. 230 
  securities under scheme(s) 
  from previous return: 
                                       2. 12,864 
                                       3. 193,055* 
                                       4. 116,296 
                                ------------------------------------------------------ 
 Plus: The amount by                  1. Nil 
  which the block scheme(s) 
  has been increased 
  since the date of 
  the last return (if 
  any increase has been 
  applied for): 
                                       2. Nil 
                                       3. 350,000 
                                       4. 60,000 
                                ------------------------------------------------------ 
 Less: Number of securities           1. Nil 
  issued / allotted 
  under scheme(s) during 
  period: 
                                       2. Nil 
                                       3. 150,600 
                                       4. 107,903 
                                ------------------------------------------------------ 
 Equals: Balance under                1. 230 
  scheme(s) not yet 
  issued / allotted 
  at end of period: 
                                       2. 12,864 
                                       3. 392,455 
                                       4. 68,393 
                                ------------------------------------------------------ 
 Number and class of                  1. 114,302 Ordinary Shares admitted on 
  securities originally                11 January 2021 and 1,535 Ordinary Shares 
  listed and the date                  admitted on 1 September 2021 
  of admission:                        2. 296,069 Ordinary Shares admitted on 
                                       1 September 2021 
                                       3. 350,000 Ordinary Shares admitted on 
                                       30 December 2021 
                                       4. 120,000 Ordinary Shares admitted on 
                                       15 May 2023 
                                ------------------------------------------------------

*Incorrectly stated as 199,633 in the previous Block Listing Interim Review announcement on 12 July 2023.

The Company currently has ordinary shares of 0.2 pence each block listed under the following share plans:

   1.    CVS Group plc 2017-2020 Sharesave Scheme; and 
   2.    CVS Group plc 2018-2021 SAYE Sharesave Scheme;

All outstanding share awards under the 2017 Sharesave Scheme have now vested or have lapsed and all outstanding options under the 2018 SAYE Sharesave Scheme have now been exercised or have lapsed. As a result, the block listings associated with these share plans have been cancelled and the above consists of their final block listing return.

Contacts:

CVS Group plc via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR)

Geoffrey Pelham-Lane +44 (0)7733 124 226

Ginny Pulbrook +44 (0)7961 315 138

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRUASARSRUAAUR

(END) Dow Jones Newswires

January 12, 2024 02:00 ET (07:00 GMT)

CVS (AQSE:CVSG.GB)
過去株価チャート
から 11 2024 まで 12 2024